Zobrazeno 1 - 6
of 6
pro vyhledávání: '"I F Uchegbu"'
Publikováno v:
Annals of the Rheumatic Diseases. 81:713.1-713
BackgroundSystemic sclerosis (SSc) is an immune-mediated connective tissue disease with clinical hallmark of inflammation, vasculopathy and fibrosis resulting in abnormal collagen and intercellular matrix formation in the dermis and internal organ. S
Autor:
A, Lalatsa, A G, Schätzlein, N L, Garrett, J, Moger, Michael, Briggs, Lisa, Godfrey, Antonio, Iannitelli, Jay, Freeman, I F, Uchegbu
Publikováno v:
Journal of controlled release : official journal of the Controlled Release Society. 197
The clinical development of neuropeptides has been limited by a combination of the short plasma half-life of these drugs and their ultimate failure to permeate the blood brain barrier. Peptide nanofibres have been used to deliver peptides across the
Autor:
I F, Uchegbu, L, Sadiq, M, Arastoo, A I, Gray, W, Wang, R D, Waigh, A G, Schätzlein, A G, Schätzleinä
Publikováno v:
International journal of pharmaceutics. 224(1-2)
A new polysoap, quaternary ammonium palmitoyl glycol chitosan (GCPQ, M(w)=178,000 g mole(-1)) with drug solubilising potential has been synthesised and characterised. In solution hydrophobic domains of GCPQ polymeric micelles were identified by the h
Autor:
C, Dufes, A G, Schätzlein, L, Tetley, A I, Gray, D G, Watson, J C, Olivier, W, Couet, I F, Uchegbu
Publikováno v:
Pharmaceutical research. 17(10)
To prepare polymeric vesicles and niosomes bearing glucose or transferrin ligands for drug targeting.A glucose-palmitoyl glycol chitosan (PGC) conjugate was synthesised and glucose-PGC polymeric vesicles prepared by sonication of glucose-PGC/choleste
Publikováno v:
Pharmaceutical research. 12(7)
Encapsulation of doxorubicin in niosomes was sought as a route to tumour targeting and improved tumoricidal through the alteration of doxorubicin pharmacokinetics and metabolism.Doxorubicin niosomes (10 mg kg-1 doxorubicin) prepared from sorbitan mon
Publikováno v:
Physics in Medicine & Biology; Jan2008, Vol. 53 Issue 2, p505-513, 9p